Kumaraguru Raja
Stock Analyst at Brookline Capital
(n/a)
# 4,783
Out of 4,784 analysts
15
Total ratings
8.33%
Success rate
-55.12%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kumaraguru Raja
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| QNCX Quince Therapeutics | Initiates: Buy | $9 | $1.35 | +566.67% | 1 | Dec 18, 2024 | |
| PALI Palisade Bio | Initiates: Buy | $38 | $0.69 | +5,417.64% | 1 | Nov 20, 2024 | |
| SABS SAB Biotherapeutics | Initiates: Buy | $8 | $1.48 | +440.54% | 1 | Jun 7, 2024 | |
| FBRX Forte Biosciences | Initiates: Buy | $100 | $8.20 | +1,119.51% | 2 | May 30, 2024 | |
| HEPA Hepion Pharmaceuticals | Downgrades: Hold | n/a | $0.48 | - | 1 | Dec 7, 2023 | |
| OTLK Outlook Therapeutics | Downgrades: Hold | n/a | $1.32 | - | 1 | Aug 30, 2023 | |
| ADIL Adial Pharmaceuticals | Reiterates: Buy | $150 | $0.67 | +22,378.65% | 2 | Jul 11, 2023 | |
| GNTA Genenta Science | Assumes: Buy | $15 | $3.97 | +277.83% | 1 | Jun 29, 2023 | |
| RAIN Rain Enhancement Technologies Holdco | Reinstates: Buy | $21 | $1.98 | +960.61% | 1 | Jan 31, 2023 | |
| MNPR Monopar Therapeutics | Reinstates: Buy | $90 | $40.33 | +123.16% | 1 | Dec 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $29 → $31 | $0.51 | +6,001.16% | 2 | May 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $3,360 | $1.18 | +284,645.76% | 1 | Sep 21, 2021 |
Quince Therapeutics
Dec 18, 2024
Initiates: Buy
Price Target: $9
Current: $1.35
Upside: +566.67%
Palisade Bio
Nov 20, 2024
Initiates: Buy
Price Target: $38
Current: $0.69
Upside: +5,417.64%
SAB Biotherapeutics
Jun 7, 2024
Initiates: Buy
Price Target: $8
Current: $1.48
Upside: +440.54%
Forte Biosciences
May 30, 2024
Initiates: Buy
Price Target: $100
Current: $8.20
Upside: +1,119.51%
Hepion Pharmaceuticals
Dec 7, 2023
Downgrades: Hold
Price Target: n/a
Current: $0.48
Upside: -
Outlook Therapeutics
Aug 30, 2023
Downgrades: Hold
Price Target: n/a
Current: $1.32
Upside: -
Adial Pharmaceuticals
Jul 11, 2023
Reiterates: Buy
Price Target: $150
Current: $0.67
Upside: +22,378.65%
Genenta Science
Jun 29, 2023
Assumes: Buy
Price Target: $15
Current: $3.97
Upside: +277.83%
Rain Enhancement Technologies Holdco
Jan 31, 2023
Reinstates: Buy
Price Target: $21
Current: $1.98
Upside: +960.61%
Monopar Therapeutics
Dec 9, 2022
Reinstates: Buy
Price Target: $90
Current: $40.33
Upside: +123.16%
May 18, 2022
Maintains: Buy
Price Target: $29 → $31
Current: $0.51
Upside: +6,001.16%
Sep 21, 2021
Initiates: Buy
Price Target: $3,360
Current: $1.18
Upside: +284,645.76%